ELDN FY2025 EPS Estimate Reduced by Cantor Fitzgerald

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for shares of Eledon Pharmaceuticals in a report issued on Monday, March 24th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings of ($1.23) per share for the year, down from their previous estimate of ($1.12). The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($0.81) per share.

Separately, Guggenheim began coverage on shares of Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They issued a "buy" rating and a $9.00 price objective on the stock.

Eledon Pharmaceuticals Price Performance

NASDAQ:ELDN traded down $0.06 during trading hours on Wednesday, reaching $3.35. 179,340 shares of the stock were exchanged, compared to its average volume of 278,529. The stock has a market cap of $200.60 million, a PE ratio of -1.67 and a beta of 0.80. Eledon Pharmaceuticals has a twelve month low of $1.52 and a twelve month high of $5.54. The firm has a 50 day moving average of $4.12 and a 200 day moving average of $3.89.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.32). During the same period in the prior year, the business earned ($1.00) earnings per share.

Institutional Trading of Eledon Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. RA Capital Management L.P. acquired a new position in Eledon Pharmaceuticals during the fourth quarter valued at approximately $14,693,000. First Light Asset Management LLC bought a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $9,595,000. Blue Owl Capital Holdings LP acquired a new stake in shares of Eledon Pharmaceuticals in the 4th quarter valued at approximately $8,075,000. Sphera Funds Management LTD. grew its stake in shares of Eledon Pharmaceuticals by 96.7% in the fourth quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company's stock valued at $10,513,000 after buying an additional 1,254,298 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. acquired a new position in Eledon Pharmaceuticals during the fourth quarter worth $4,848,000. Institutional investors and hedge funds own 56.77% of the company's stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).